New study shows prescribing of newer antipsychotic medication risperdal may save millions in schizoph...( 11th July 2000 Brussels -- Treatment...)

New study shows prescribing of newer antipsychotic medication risperdal may save millions in schizophrenia care

11th July 2000, Brussels -- Treatment with the newer antipsychotic medication Risperdal® (risperidone) for patients with schizophrenia could have the potential to save millions of dollars from healthcare budgets across the world, according to a major new study presented at the Collegium Internationale Neuro-Psychopharmacologicum (CINP) meeting in Belgium.

The study evaluated the cost-effectiveness (1,901 patients, 61 centres, 9 countries) of newer treatments for schizophrenia and showed that treating patients with schizophrenia with Risperdal, versus olanzapine, resulted in a saving of $2.80 US per patient per day1. This corresponds to a saving of $1,022 US per patient per year ($2.80 X 365 days).

Schizophrenia is a common serious mental illness. It is estimated that one person in every 100 worldwide will develop schizophrenia by the age of 45, with men and women equally at risk2.

Dr Koen Torfs, Head of Health Economics and Outcomes Research at Janssen Pharmaceutica explained, "We already know that the newer medicines for schizophrenia are both more cost-effective and have fewer side effects than older medicines, this can in turn encourage patients to stay on therapy long-term. However, this new study adds further knowledge to our understanding about the cost-effectiveness between the newer therapies for schizophrenia and the possible impacts they may have on healthcare budgets around the world".

Studies directly comparing the cost effectiveness between the new schizophrenia treatments are vital to justify modern prescribing decisions. "This new data from the RODOS study1 now answers long-standing questions about the differences in cost and effectiveness between these new treatments, and provides doctors and healthcare providers with the evidence they need to ensure cost-effective prescribing for schizophrenia", said Professor Siegfried Kasper MD, Professor and Chairman, Department of General Psychiatry, University of Vienna.

The
'"/>

Contact: Tamsin Page
tamsin.page@ketchumcomms.co.uk
44-207-465-7688
Ketchum
10-Jul-2000

Page: 1 2 3
Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. UMaine study looks at infants and chronic nighttime crying
3. Chronic pain treatments more effective when taken together, new study shows
4. UNC study: Most N.C. family practitioners engage in unrecognized community service
5. New study in Nature demonstrates protection against cell death during heart attack
6. UCSF study offers insight into human circadian rhythms
7. International breast cancer prevention study launches in the United States and Canada
8. UW study shows blacks and Latinos are more satisfied with physicians of the same race
9. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
10. Advertising by academic medical centers may risk eroding public trust, says study
11. Fat may promote inflammation, new study suggests

Post Your Comments: